TN2009000518A1 - Particulates of a crth2 antagonist - Google Patents

Particulates of a crth2 antagonist

Info

Publication number
TN2009000518A1
TN2009000518A1 TNP2009000518A TN2009000518A TN2009000518A1 TN 2009000518 A1 TN2009000518 A1 TN 2009000518A1 TN P2009000518 A TNP2009000518 A TN P2009000518A TN 2009000518 A TN2009000518 A TN 2009000518A TN 2009000518 A1 TN2009000518 A1 TN 2009000518A1
Authority
TN
Tunisia
Prior art keywords
particulates
crth2 antagonist
crth2
benzamido
pyrimidin
Prior art date
Application number
TNP2009000518A
Other languages
English (en)
Inventor
Tai Wei Ly
Hui-Yin Li
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000518(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of TN2009000518A1 publication Critical patent/TN2009000518A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TNP2009000518A 2007-06-21 2009-12-10 Particulates of a crth2 antagonist TN2009000518A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93697207P 2007-06-21 2007-06-21
PCT/US2008/007589 WO2008156780A1 (fr) 2007-06-21 2008-06-18 Particules d'antagoniste de crth2

Publications (1)

Publication Number Publication Date
TN2009000518A1 true TN2009000518A1 (en) 2011-03-31

Family

ID=39708813

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000518A TN2009000518A1 (en) 2007-06-21 2009-12-10 Particulates of a crth2 antagonist

Country Status (21)

Country Link
US (1) US8507005B2 (fr)
EP (1) EP2170838A1 (fr)
JP (1) JP2010530425A (fr)
KR (1) KR20100023046A (fr)
CN (3) CN103172573A (fr)
AR (1) AR067119A1 (fr)
AU (1) AU2008266853A1 (fr)
BR (1) BRPI0813436A2 (fr)
CA (1) CA2690172A1 (fr)
CL (1) CL2008001818A1 (fr)
CO (1) CO6290713A2 (fr)
EC (1) ECSP109890A (fr)
HK (1) HK1144939A1 (fr)
IL (1) IL202679A0 (fr)
MA (1) MA31534B1 (fr)
NZ (1) NZ581811A (fr)
RU (1) RU2468012C2 (fr)
TN (1) TN2009000518A1 (fr)
TW (1) TW200911762A (fr)
UA (1) UA99138C2 (fr)
WO (1) WO2008156780A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1471057T3 (da) 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
CN101772489B (zh) * 2007-06-21 2013-02-20 艾克提麦斯医药品有限公司 一种crth2拮抗剂的胺盐
KR101235961B1 (ko) 2008-02-01 2013-02-21 판미라 파마슈티칼스, 엘엘씨 프로스타글란딘 ｄ２ 수용체의 ｎ,ｎ-이치환 아미노알킬비페닐 길항제
EP2245022A4 (fr) 2008-02-25 2012-02-22 Panmira Pharmaceuticals Llc Antagonistes des récepteurs d2 de la prostaglandine
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (fr) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Antagonistes d’hétéroaryle des récepteurs de la prostaglandine d2
WO2010042652A2 (fr) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Antagonistes hétéroalkyl biphényle des récepteurs de la prostaglandine d2
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2011005645A1 (fr) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Polymorphe de [4,6-bis(diméthylamino)-2-(4-{[4-(trifluorométhyl)benzoyl]amino}benzyl)pyrimidin-5-yl] acétique
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
EP2504318A2 (fr) 2009-11-24 2012-10-03 Boehringer Ingelheim International GmbH Nouvelles formes salines d'un dérivé de l'acide pyrimidin-5-yl acétique
JP2013512242A (ja) 2009-11-24 2013-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリミジン−５−イル酢酸誘導体のコリン塩の多形体を調製する方法
EP2457900A1 (fr) 2010-11-25 2012-05-30 Almirall, S.A. Nouveaux dérivés de pyrazole présentant un comportement antagoniste CRTH2
EP3638208A1 (fr) * 2017-06-12 2020-04-22 Novartis AG Matériaux pharmaceutiques nanostructurés amorphes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078690B2 (en) * 2002-02-04 2006-07-18 Applied Materials, Israel, Ltd. Monitoring of contact hole production
DK1471057T3 (da) * 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
MXPA06007674A (es) * 2004-01-31 2006-09-04 Actimis Pharmaceuticals Inc Derivados del acido imidazo [1,2-c] pirimidinilacetico.

Also Published As

Publication number Publication date
NZ581811A (en) 2012-11-30
UA99138C2 (ru) 2012-07-25
MA31534B1 (fr) 2010-07-01
CO6290713A2 (es) 2011-06-20
RU2010101804A (ru) 2011-07-27
RU2468012C2 (ru) 2012-11-27
CL2008001818A1 (es) 2009-03-06
CN101778830B (zh) 2013-03-20
JP2010530425A (ja) 2010-09-09
EP2170838A1 (fr) 2010-04-07
AU2008266853A1 (en) 2008-12-24
CN103172573A (zh) 2013-06-26
IL202679A0 (en) 2010-06-30
BRPI0813436A2 (pt) 2014-12-23
CA2690172A1 (fr) 2008-12-24
HK1144939A1 (en) 2011-03-18
CN101778830A (zh) 2010-07-14
AR067119A1 (es) 2009-09-30
US20110052701A1 (en) 2011-03-03
WO2008156780A1 (fr) 2008-12-24
CN103172572A (zh) 2013-06-26
TW200911762A (en) 2009-03-16
KR20100023046A (ko) 2010-03-03
ECSP109890A (es) 2010-03-31
US8507005B2 (en) 2013-08-13

Similar Documents

Publication Publication Date Title
HK1144939A1 (en) Particulates of a crth2 antagonist crth2
HK1144940A1 (en) Amine salts of a crth2 antagonist
WO2008067399A3 (fr) Formulation à libération contrôlée d'antagonistes de pipérazine-pipéridine et agonistes du récepteur 5-ht1a ayant une dissolution intestinale amplifiée
UY30136A1 (es) Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
IL184125A (en) Use of 3 - z - [- 1 - (4 - (n - ((4 - methyl - piperazine - 1 - yl) - methylcarbonyl) - n - methyl - amino) anilino) - 1 - phenyl - methylene] - 6 Methoxycarbonyl-2-indulinone for the preparation or prevention of osteopathic pulmonary fibrosis
WO2009131974A8 (fr) Composes de 2-imino-3-methyl-pyrrolo pyrimidinone substitues par thiophenyle utilises en tant qu’inhibiteurs bace-1, compositions et utilisation associees
IL200793A0 (en) Aminopyrimidines, compositions comprising the same and use thereof for inhibiting protein kinases
WO2007093450A3 (fr) Derives de catecholamine deuteries et medicaments comprenant de tels composes
MY159522A (en) Administration of dipeptidyl peptidase inhibitors
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2007106181A3 (fr) Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
WO2007103970A3 (fr) Compositions et procédés de traitement de troubles respiratoires
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
SMT201300108B (it) Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina
HK1120738A1 (en) Methods and formulations for modulating lyn kinase activity and treating related disorders
EA200970875A1 (ru) Производные индолизинуксусной кислоты в качестве антагонистов crth2
RS54293B1 (en) PHARMACEUTICAL COMBINATION
MX2011009506A (es) Antagonista del receptor mineralcorticoide y metodos de uso.
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
WO2011066147A3 (fr) Nouvelles formes salines d'un dérivé de l'acide pyrimidin-5-yl acétique
PL376713A1 (pl) Zastosowanie pochodnych kwasu piperazynosulfonowego jako antagonistów CCR1 do leczenia zwłóknienia, choroby Alzheimera i innych zaburzeń